Brian Culley compensation by year
Lineage Cell Therapeutics Summary Compensation Table · all 8 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Salary | $154,923 | $535,800 | $551,900 | $580,000 | $609,000 | $639,500 | $665,100 | $691,800 |
| Bonus | $0 | $214,300 | $262,200 | $319,000 | $0 | $0 | $0 | $0 |
| Stock awards | $693,000 | $0 | $0 | $0 | $268,503 | $0 | $0 | $0 |
| Option awards | $1,917,320 | $0 | $521,563 | $1,840,975 | $1,159,875 | $1,918,430 | $1,502,900 | $882,970 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $319,900 | $330,700 | $349,200 | $518,900 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $7,135 | $22,642 | $14,250 | $14,500 | $15,250 | $16,500 | $17,250 | $17,500 |
| Total | $2,772,378 | $772,742 | $1,349,913 | $2,754,475 | $2,372,528 | $2,905,130 | $2,534,450 | $2,111,170 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Lineage Cell Therapeutics, Inc. DEF 14A filed April 29, 2026, accession 0001193125-26-191556, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Lineage Cell Therapeutics, Inc. filed document, accession 0001193125-26-191556. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 147,320 | $52,186 | — |
| Option | 78,125 | — | $1.40 |
| Option | 593,750 | — | $1.46 |
| Option | 1,068,750 | — | $1.13 |
| Option | 2,300,000 | — | $0.53 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Lineage Cell Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Lineage Cell Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Brian Culley · this page | Chief Executive Officer | $2,111,170 |
| Jill Howe | Chief Financial Officer | $1,005,925 |
| George Samuel III | General Counsel and Corporate Secretary | $978,225 |
Board service
Lineage Cell Therapeutics board · FY2021–FY2025How this board is paid
Company policy: Lineage Cell Therapeutics pays directors a $50,000 cash retainer. As stated in Lineage Cell Therapeutics's FY2025 proxy.
Committees
Financial Strategy (Chair)
The full Lineage Cell Therapeutics compensation record
free company briefThis page is one person within Lineage Cell Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Lineage Cell Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Lineage Cell Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Lineage Cell Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order LCTX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.